Some serious money among this lot. Astrazenaca recently put up 2.5 billion for a cancer drug 'acalabrutinib'... there is money out there for the right asset. Interested though in your rationale for bold status.
I certainly believe Pfizer would be interested as they know and market nadolol. I wonder if these companies have real time access to the NIMA asthma trial? Dosing is complete but it won't report until mid 2016. On another note, does anyone know when toxicology will be completed for inhaled 102 and 104 so that we can get FDA IND status? or has this been put on hold through lack of funding?
IVX Price at posting:
0.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)